The Health Resources and Services Administration (HRSA) within HHS has finalized a rule for all drug manufacturers who are required to make their drugs available to covered care providers under the 340B drug pricing program.
The Health Resources and Services Administration (HRSA) within HHS has finalized a rule for all drug manufacturers who are required to make their drugs available to covered care providers under the 340B drug pricing program. This final rule now sets the 340B ceiling price and application of civil monetary penalties.
The final rule was developed after considering all the comments received by HRSA during the general comment period. Under the new rule, the HRSA can fine a manufacturer up to $5000 for each incident of knowing and intentional overcharging of 340B hospitals for drugs that were purchased under the program. The rule includes information for manufacturers to calculate the 340B ceiling price and the imposition of CMPs against manufacturers who knowingly and intentionally overcharged a covered entity.
The regulation also requires manufacturers to offer refunds for overcharges on new drugs instead of maintaining the current rule, which needs covered entities to request refunds. The rule also gives the Office of the Inspector General authority to impose those penalties. However, there is some wiggle room. Manufacturers would not be considered to have the requisite intent if:
340B Health, an organization that has a membership of public and private nonprofit hospitals and health systems that participate in the 340B Drug Pricing Program, released a statement that welcomes the final rule: “Today’s new 340B drug discount program rule should help prevent the drug industry from overcharging America’s 340B health providers for lifesaving medicines. It’s a welcome development in light of public outrage about the unsustainable cost of prescription drugs." The specifics in the rule on how 340B ceiling prices should be calculated will ensure that the prices are right, the statement affirmed.
The release noted that the economic impact of the final rule will not exceed $100 million in a year, and so is not designated to be “economically significant.” The total savings from the 340B Program as a whole are estimated at $6 billion in 2015 alone.
HRSA will begin enforcing the rule from April 1, 2017, anticipating that drug manufacturers will have sufficient time from now until the effective date to update their policies and procedures.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More